TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer

Clinical trial NCT06532799 · RECRUITING

Trial details

NCT number: NCT06532799
Sponsor: Essen Biotech
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Stomach Cancer Stomach Cancer Recurrent Stomach Cancer, Adenocarcinoma Esophageal Cancer Esophageal Cancer Metastatic to Bone Esophageal Cancer Metastatic to Lung Esophageal Cancer Metastatic to Liver

Start date: 2024-09-10
Primary completion: 2025-12-15
Enrollment: 75

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.